Vanguard Group
BEAM icon

Vanguard Group’s Beam Therapeutics BEAM Stock Holding History

Vanguard Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$255M Sell
9,193,474
-57,310
-0.6% -$1.46M ﹤0.01% 1410
2025
Q3 		$225M Sell
9,250,784
-455,440
-5% -$9.06M ﹤0.01% 1491
2025
Q2 		$165M Buy
9,706,224
+834,932
+9% +$14.5M ﹤0.01% 1601
2025
Q1 		$173M Buy
8,871,292
+1,249,303
+16% +$32.7M ﹤0.01% 1544
2024
Q4 		$189M Sell
7,621,989
-222,617
-3% -$5.68M ﹤0.01% 1568
2024
Q3 		$192M Sell
7,844,606
-55,773
-0.7% -$1.44M ﹤0.01% 1561
2024
Q2 		$185M Buy
7,900,379
+321,611
+4% +$7.9M ﹤0.01% 1529
2024
Q1 		$250M Buy
7,578,768
+413,892
+6% +$12.9M 0.01% 1375
2023
Q4 		$195M Buy
7,164,876
+349,906
+5% +$8.69M ﹤0.01% 1517
2023
Q3 		$164M Sell
6,814,970
-195,009
-3% -$5.23M ﹤0.01% 1539
2023
Q2 		$224M Buy
7,009,979
+624,488
+10% +$20.3M 0.01% 1420
2023
Q1 		$196M Buy
6,385,491
+111,861
+2% +$4.41M 0.01% 1466
2022
Q4 		$245M Buy
6,273,630
+99,159
+2% +$4.44M 0.01% 1325
2022
Q3 		$294M Buy
6,174,471
+927,970
+18% +$52.9M 0.01% 1147
2022
Q2 		$203M Buy
5,246,501
+534,491
+11% +$21.2M 0.01% 1416
2022
Q1 		$270M Buy
4,712,010
+14,745
+0.3% +$967K 0.01% 1352
2021
Q4 		$374M Buy
4,697,265
+180,565
+4% +$15.5M 0.01% 1182
2021
Q3 		$393M Buy
4,516,700
+1,081,128
+31% +$109M 0.01% 1132
2021
Q2 		$442M Buy
3,435,572
+202,162
+6% +$16.1M 0.01% 1070
2021
Q1 		$259M Buy
3,233,410
+417,780
+15% +$39.7M 0.01% 1433
2020
Q4 		$230M Buy
2,815,630
+567,257
+25% +$27.9M 0.01% 1391
2020
Q3 		$55.4M Buy
2,248,373
+1,082,753
+93% +$26.9M ﹤0.01% 1967
2020
Q2 		$32.6M Buy
1,165,620
+1,071,678
+1,141% +$23.1M ﹤0.01% 2205
2020
Q1 		$1.69M Buy
+93,942
New +$2.04M ﹤0.01% 3349

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group's BEAM Position: Q4 2025 in Review

Vanguard Group reduced its Beam Therapeutics (BEAM) stake by 0.62% in Q4 2025, selling an estimated $1.46M and leaving 9,193,474 shares worth $255M. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Vanguard Group first reported a position in BEAM in Q1 2020 and has held it in 24 quarters since. The position peaked at $442M in Q2 2021. 247 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Vanguard Group held 9,193,474 shares of Beam Therapeutics worth $255M as of Q4 2025.
  • Vanguard Group sold 57,310 Beam Therapeutics shares in Q4 2025, an estimated $1.46M.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1410 holding.
  • Vanguard Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Vanguard Group's Beam Therapeutics position peaked at $442M in Q2 2021.
  • 247 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.